{
    "nct_id": "NCT04965493",
    "official_title": "A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)",
    "inclusion_criteria": "* Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria\n* Previous treatment with at least one line of therapy that may include a covalent Bruton's tyrosine kinase (BTK) inhibitor\n* Platelets greater than or equal to (≥)50 x 10⁹/liter (L), hemoglobin ≥8 grams/deciliter (g/dL) and absolute neutrophil count ≥1.0 x 10⁹/L\n* Adequate organ function\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Estimated creatinine clearance ≥30 milliliters per minute (mL/min)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known or suspected Richter's transformation at any time preceding enrollment\n* Prior therapy with a non-covalent (reversible) BTK inhibitor\n* Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist\n* Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers\n* Prior therapy with venetoclax\n* Central nervous system (CNS) involvement\n* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count\n* Allogeneic stem cell transplantation (SCT) or chimeric antigen receptor (CAR)-T within 60 days\n* Active hepatitis B or hepatitis C\n* Known active cytomegalovirus (CMV) infection\n* Uncontrolled immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia (AIHA)\n* Significant cardiovascular disease\n* Vaccination with a live vaccine within 28 days prior to randomization\n* Patients with the following hypersensitivity:\n\n  * Known hypersensitivity to any component or excipient of pirtobrutinib and venetoclax\n  * Prior significant hypersensitivity to rituximab\n  * Known allergy to allopurinol and inability to take uric acid lowering agent",
    "miscellaneous_criteria": ""
}